



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 4027

Title: Efficacy of switching to telbivudine plus adefovir in suboptimal responder to lamivudine plus adefovir

Reviewer code: 02462130

Science editor: Zhai, Huan-Huan

Date sent for review: 2013-06-14 08:54

Date reviewed: 2013-06-15 10:33

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Ms: ESPS Manuscript No.4027 Comments on "Efficacy of switching to telbivudine plus adefovir in suboptimal responder to lamivudine plus adefovir" are as below: The authors described comparison of combination therapy of telbivudine plus adefovir vs lamivudine plus adefovir. This is the first comparison study about these 2 different combination therapies. This information is very important for future antiviral therapy of chronic B hepatitis. Furthermore, study design of this study is well organized and data is analyzed very well. It should be published in "World Journal of Gastroenterology". Acceptance after simple modifications is recommended. Can author add comparison data of side effects between these 2 different combination therapies in Table 2? Confidential comments: Switching to this combination therapy may be an additional therapeutic strategy for chronic hepatitis B in suboptimal responder to lamivudine plus adefovir. I believe this is a very nice paper, which many hepatologists are interested in, with high quality. Thus, it is highly worthy to be published in "World Journal of Gastroenterology". Acceptance after minimum modifications is recommended. Jun 14th, 2013 (Additional evaluation) Classification of the manuscript: Grade A Language evaluation: Grade